Skip to main
HUM
HUM logo

Humana (HUM) Stock Forecast & Price Target

Humana (HUM) Analyst Ratings

Based on 16 analyst ratings
Hold
Strong Buy 6%
Buy 31%
Hold 63%
Sell 0%
Strong Sell 0%

Bulls say

Humana's increased 2025 earnings per share (EPS) estimate to $17.06 reflects strong second-quarter results and revised guidance, indicating a positive financial trajectory. The company's focus on margin initiatives is expected to drive year-over-year earnings growth in 2027, despite a stable star rating assumption for that year. Additionally, Humana's above-industry Medicare Advantage star rating positions it competitively, particularly in light of evolving regulatory and reimbursement conditions, providing a robust foundation for future performance.

Bears say

Humana's financial outlook is challenged by expected declines in earnings per share (EPS) for 2026, primarily due to headwinds related to MA Stars ratings and the anticipation of increased competition in the Medicare Advantage (MA) sector. Furthermore, the company faces additional downside risks including inadequate reimbursement rates, a reduction in PDP membership, and slower growth in its Healthcare Services division, which collectively threaten future profitability. For FY27, the potential shortfall of approximately 10% in EPS estimates highlights the impact of necessary investments aimed at recovering MA Stars ratings, indicating ongoing financial pressures.

Humana (HUM) has been analyzed by 16 analysts, with a consensus rating of Hold. 6% of analysts recommend a Strong Buy, 31% recommend Buy, 63% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Humana and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Humana (HUM) Forecast

Analysts have given Humana (HUM) a Hold based on their latest research and market trends.

According to 16 analysts, Humana (HUM) has a Hold consensus rating as of Nov 27, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $298.69, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $298.69, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Humana (HUM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.